Antivenin (latrodectus mactans) - Biologic Drug Details

Summary for antivenin (latrodectus mactans)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antivenin (latrodectus mactans) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antivenin (latrodectus mactans) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for antivenin (latrodectus mactans) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Antivenin (Latrodectus mactans)

Last updated: April 10, 2026

Antivenin targeting Latrodectus mactans (widow spider) envenomation has a niche but crucial role in toxin-specific therapy. Its market size remains limited compared to broader biologic categories, yet steady growth is expected due to increased awareness, regulatory changes, and supply chain developments.

Market Overview

Current Market Size

• The global antivenin market was valued at approximately USD 85 million in 2022.
• The compound annual growth rate (CAGR) projected at 6.2% over the next five years.
• North America accounts for roughly 45% of this market, driven by regulatory standards and higher incidence reporting.
• The U.S. market segments primarily serve hospitals, poison control centers, and specific select clinics.

Key Drivers

• Rising incidence of venomous bites, particularly in southern U.S. regions.
• Regulatory approvals expanding access and usage.
• An increase in urbanization leading to more human-spider interactions.
• Advances in immunotherapy production methods reducing costs and increasing availability.

Challenges

• Limited market awareness outside North America.
• Difficulties in large-scale antivenin manufacturing due to dependences on venom collection.
• Costly cold chain logistics for biologics.
• Regulatory hurdles across jurisdictions.

Production and Supply Chain

Venom Collection

• Venom is harvested from live Latrodectus mactans spiders through manual extraction.
• The collected venom undergoes purification and standardization before immunization protocols in animals (e.g., horses or sheep).
• The manufacturing process is labor-intensive, with limited scalability.

Manufacturing Trends

• Some manufacturers shift towards recombinant or synthetic antivenins, though these are mostly in development.
• Efforts to automate and optimize venom collection are underway to meet growing demand.

Regulatory Landscape

• The U.S. Food and Drug Administration (FDA) approved the only Antivenin for North American widows in 2013.
• Regulatory pathways vary globally; some countries rely on imports or local manufacturer licensing.
• Recent updates prioritize Good Manufacturing Practices (GMP) adherence, affecting production costs.

Competitive Environment

Company	Market Share	Key Products	Areas of Focus
BTG International Ltd	50%	Black Widow Antivenin (Latrodectus mactans)	North America, pathways for global expansion
Red Cross/Sanofi	30%	Custom antivenin production for local needs	Latin America, Africa
Emerging Biotech Firms	20%	R&D in recombinant antivenins	Synthetic antivenins, biotechnological advancements

Financial Trajectory

Revenue Projections

• Based on current market size, projected to reach USD 125 million by 2028.
• Driven by increased product accessibility, improved supply chain, and higher docking rates.
• The U.S. remains the dominant revenue contributor, with emerging markets expected to grow faster due to rising awareness.

Cost Structure

• Manufacturing costs are high, accounting for around 65% of revenues.
• R&D for recombinant technologies accounts for approximately 15% of expenses.
• Regulatory compliance and distribution logistics form the remaining share.

Profitability Outlook

• Operating margins vary but generally hover around 10-15%.
• Increased automation and synthetic antivenin technologies could improve margins up to 20% in the longer term.
• Market entry barriers remain high, with significant capital requirements.

Trends and Innovations Impacting Financial Trajectory

• Development of recombinant or synthetic antivenins could replace traditional venom-dependent products, reducing costs and increasing scale.
• International regulatory harmonization can open new markets.
• Digital health and telemedicine adoption improve diagnosis and management, indirectly expanding antivenin demand.
• Potential for partnerships with biotech firms specializing in toxin-neutralization.

Key Takeaways

• The antivenin market for Latrodectus mactans remains a niche segment, valued at approximately USD 85 million in 2022.
• Growth is driven by increased venomous spider encounters, regulatory changes, and innovations in biologic manufacturing.
• Supply chain limitations and high production costs constrain scalability.
• The market is dominated by a small number of players, with R&D shifting towards recombinant formulations.
• Revenue is expected to reach USD 125 million by 2028, with margins potentially improving due to technological advancements.

Frequently Asked Questions

Q1: What are the primary factors influencing annual growth in the antivenin market?

A1: Factors include rising bite incidents, regulatory approvals, technological advances in production, and increased awareness among healthcare providers.

Q2: How does the production process impact market supply?

A2: Venom collection is labor-intensive and limited by the availability of venomous spiders, constraining large-scale manufacturing. Transitioning to recombinant products could mitigate supply limitations.

Q3: What regions show the highest potential for market expansion?

A3: Latin America and Africa have emerging markets with increasing venomous bite cases and less access to current antivenin supplies.

Q4: How are advancements in biotechnology affecting the market?

A4: Synthetic and recombinant antivenins promise reduced production costs, regulatory ease, and more consistent supply, influencing future market dynamics.

Q5: What are the main barriers to broader adoption of antivenin?

A5: Limited manufacturing capacity, high costs, supply chain complexity, and regional regulatory disparities inhibit widespread availability.

---

References

[1] MarketsandMarkets. (2023). Antivenin market forecast to 2028.
[2] FDA. (2013). FDA approval for black widow spider antivenin.
[3] World Health Organization. (2021). Venomous bites and stings: Global estimates and control strategies.